Ellie’s previous experience includes several years working on innovative antibody therapeutics at Takeda, Adaptate Therapeutics and Kymab Ltd. Ellie has a PhD from Cardiff University working with the Wellcome Trust Sanger Institute to identify NK cell expressed genes involved in MCMV infection control and a Pharmacology degree from the University of Bath.

At RQ Bio, Ellie applies her expertise in antibody discovery to characterise novel neutralising antibodies for protecting vulnerable patients from emerging viral infections.